Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) from a hold rating to a buy rating in a report released on Wednesday morning. Zacks Investment Research currently has $6.25 target price on the biopharmaceutical company’s stock.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
TTPH has been the subject of several other research reports. Needham & Company LLC reaffirmed a hold rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. BMO Capital Markets reaffirmed a buy rating and issued a $12.00 price objective on shares of Tetraphase Pharmaceuticals in a report on Friday, May 5th. Stifel Nicolaus raised shares of Tetraphase Pharmaceuticals from a hold rating to a buy rating and upped their price objective for the stock from $8.00 to $15.00 in a report on Wednesday, July 26th. Finally, HC Wainwright started coverage on shares of Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They issued a buy rating and a $15.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Tetraphase Pharmaceuticals has a consensus rating of Hold and an average target price of $10.65.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down 1.29% during mid-day trading on Wednesday, hitting $5.35. 1,615,612 shares of the company traded hands. The firm’s market cap is $273.13 million. Tetraphase Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $9.93. The firm has a 50-day moving average price of $6.97 and a 200 day moving average price of $6.94.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.76) by $0.07. The company had revenue of $1.59 million during the quarter, compared to analyst estimates of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The business’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.47) EPS. Equities research analysts anticipate that Tetraphase Pharmaceuticals will post ($2.55) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://sportsperspectives.com/2017/08/13/tetraphase-pharmaceuticals-inc-nasdaqttph-upgraded-to-buy-by-zacks-investment-research.html.
A number of large investors have recently modified their holdings of the stock. Tekla Capital Management LLC increased its stake in shares of Tetraphase Pharmaceuticals by 422.2% in the first quarter. Tekla Capital Management LLC now owns 1,004,322 shares of the biopharmaceutical company’s stock worth $9,230,000 after buying an additional 812,000 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Tetraphase Pharmaceuticals by 73.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,101,255 shares of the biopharmaceutical company’s stock worth $7,853,000 after buying an additional 466,955 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Tetraphase Pharmaceuticals by 16.4% in the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock worth $15,061,000 after buying an additional 230,420 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Tetraphase Pharmaceuticals by 108.2% in the first quarter. Acadian Asset Management LLC now owns 379,049 shares of the biopharmaceutical company’s stock worth $3,482,000 after buying an additional 197,022 shares during the last quarter. Finally, Morgan Stanley increased its stake in shares of Tetraphase Pharmaceuticals by 112.1% in the first quarter. Morgan Stanley now owns 317,717 shares of the biopharmaceutical company’s stock worth $2,919,000 after buying an additional 167,919 shares during the last quarter. 35.76% of the stock is owned by institutional investors.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.